Media Centre

Featured Media Release

06 Mar 2013 - Fluarix® Product Notification

GlaxoSmithKline Australia (GSK) in consultation with the Therapeutic Goods Administration (TGA) has issued a product notification to healthcare professionals for its influenza vaccine Fluarix (Inactivated Split Influenza Vaccine).


Media Releases

Information on the availability of Boostrix

GSK confirms uninterrupted supply of Boostrix to the National Immunisation Program (NIP) and state-based vaccination programs using Boostrix in Australia.



GSK responds to devastation in Vanuatu

GSK today has announced it will be providing a monetary donation of £50,000 (~AUD 97,000) to international children’s charity Save the Children Australia to support relief efforts following the trail of destruction left by Cyclone Pam.



GSK completes major three-part transaction with Novartis

Completion of this transaction represents a major step forward in the Group’s strategy to create a stronger and more balanced set of businesses across Pharmaceuticals, Consumer Healthcare and Vaccines.



Sun Pharma to buy GSK’s Opiates business in Australia

GlaxoSmithKline (GSK) and Sun Pharmaceutical Industries Ltd. today announced that their respective wholly owned subsidiaries have reached an agreement related to GSK’s Opiates business in Australia.



Supply update: Zovirax Ophthalmic Ointment (aciclovir 3%)

Regrettably, Zovirax Ophthalmic Ointment (aciclovir 3%) continues to be impacted by a global supply constraint and is unlikely to be available in Australia prior to September 2015.



GSK statement on affordability of vaccines in developing countries

Around 80% of all of GSK’s vaccines, including our pneumococcal vaccine, are provided to developing countries at a substantial discount to western prices. GSK offers the lowest prices to Gavi and UNICEF which can be as little as a tenth of developed...



ADELAIDE HILLS BUSHFIRES: Donation of asthma medication

GSK has responded to the South Australian bushfire emergency by providing eight pharmacies in the Adelaide Hills fire affected areas with a donation of asthma rescue medicine.



Anoro® Ellipta® (umeclidinium/vilanterol) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease

GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) have welcomed news that Anoro Ellipta (umeclidinium/vilanterol) will be reimbursed via the Australian Pharmaceutical Benefits Scheme (PBS) as a long-term once-daily, maintenance...



Breo® Ellipta® (fluticasone furoate/vilanterol) to be PBS listed as reimbursed treatment for asthma and COPD

Affordable treatment options for Australian patients with asthma and chronic obstructive pulmonary disease (COPD) are set to expand with GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) announcing the listing of Breo Ellipta on the...



Incruse® Ellipta® (umeclidinium) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease

GlaxoSmithKline (GSK) has welcomed the listing of Incruse Ellipta (umeclidinium) on the Australian Pharmaceutical Benefits Scheme (PBS) from December 1st 2014 as a long term once-daily, maintenance bronchodilator treatment to relieve symptoms in...


1 2 3 4 5 6 7 8 9 10 11 >